Have a feature idea you'd love to see implemented?
Let us know!
VYGR Voyager Therapeutics Inc
Price (delayed)
$6.575
Market cap
$358.56M
P/E Ratio
25.29
Dividend/share
N/A
EPS
$0.26
Enterprise value
$282.43M
Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation
Highlights
VYGR's equity has surged by 69% year-on-year
Voyager Therapeutics's quick ratio has soared by 68% from the previous quarter and by 53% YoY
The revenue is down by 26% year-on-year but it is up by 21% since the previous quarter
VYGR's gross profit is down by 26% year-on-year but it is up by 21% since the previous quarter
Voyager Therapeutics's net income has shrunk by 91% YoY
Voyager Therapeutics's EPS has plunged by 89% YoY
Key stats
What are the main financial stats of VYGR
Market
Valuations
Earnings
Shares outstanding
54.53M
Market cap
$358.56M
Enterprise value
$282.43M
Price to earnings (P/E)
25.29
Price to book (P/B)
1.07
Price to sales (P/S)
2.64
EV/EBIT
N/A
EV/EBITDA
98.99
EV/Sales
1.96
Revenue
$143.77M
EBIT
-$2.02M
EBITDA
$2.85M
Free cash flow
-$22.27M
Per share
Balance sheet
Liquidity
EPS
$0.26
Free cash flow per share
-$0.39
Book value per share
$6.17
Revenue per share
$2.49
TBVPS
$7.56
Total assets
$436.23M
Total liabilities
$100.81M
Debt
$0
Equity
$335.42M
Working capital
$341.44M
Debt to equity
0
Current ratio
9.51
Quick ratio
9.33
Net debt/EBITDA
-26.68
Margins
Efficiency
Dividend
EBITDA margin
2%
Gross margin
100%
Net margin
6.3%
Operating margin
-4.6%
Return on assets
2.3%
Return on equity
3.3%
Return on invested capital
-0.8%
Return on capital employed
-0.5%
Return on sales
-1.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VYGR stock price
How has the Voyager Therapeutics stock price performed over time
Intraday
2.26%
1 week
-17.92%
1 month
8.86%
1 year
-4.57%
YTD
-22.1%
QTD
12.39%
Financial performance
How have Voyager Therapeutics's revenue and profit performed over time
Revenue
$143.77M
Gross profit
$143.77M
Operating income
-$6.65M
Net income
$9.02M
Gross margin
100%
Net margin
6.3%
The operating margin has plunged by 110% YoY but it has soared by 68% from the previous quarter
The operating income has dropped by 108% year-on-year but it has surged by 61% since the previous quarter
Voyager Therapeutics's net income has shrunk by 91% YoY
The company's net margin has shrunk by 87% YoY
Growth
What is Voyager Therapeutics's growth rate over time
Valuation
What is Voyager Therapeutics stock price valuation
P/E
25.29
P/B
1.07
P/S
2.64
EV/EBIT
N/A
EV/EBITDA
98.99
EV/Sales
1.96
Voyager Therapeutics's EPS has plunged by 89% YoY
VYGR's equity has surged by 69% year-on-year
VYGR's price to book (P/B) is 59% lower than its 5-year quarterly average of 2.6 and 33% lower than its last 4 quarters average of 1.6
VYGR's price to sales (P/S) is 27% less than its 5-year quarterly average of 3.6 and 6% less than its last 4 quarters average of 2.8
The revenue is down by 26% year-on-year but it is up by 21% since the previous quarter
Efficiency
How efficient is Voyager Therapeutics business performance
Voyager Therapeutics's ROS has plunged by 103% YoY but it has soared by 88% from the previous quarter
Voyager Therapeutics's ROIC has plunged by 100% YoY but it has soared by 90% from the previous quarter
VYGR's return on equity has dropped by 95% year-on-year
Voyager Therapeutics's return on assets has shrunk by 94% YoY
Dividends
What is VYGR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VYGR.
Financial health
How did Voyager Therapeutics financials performed over time
VYGR's current ratio has surged by 69% since the previous quarter and by 53% year-on-year
Voyager Therapeutics's quick ratio has soared by 68% from the previous quarter and by 53% YoY
The company's debt is 100% lower than its equity
VYGR's equity has surged by 69% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.